Results 21 to 30 of about 8,209 (210)

Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK Inhibitors in the BioDay Registry. [PDF]

Allergy
Allergy, Volume 81, Issue 2, Page 609-613, February 2026.
van der Gang LF, Boesjes CM, Zuithoff NPA, Haeck I, Bacoş-Cosma O, Loman L, Atash K, Harbers V, Stadhouders S, Oosting AJ, van Lynden-van Nes AMT, Politiek K, Gostynski A, Christoffers WA, Garritsen FM, Flinterman A, Touwslager WRH, Velstra B, Stewart SM, van Erp FC, Galimont-Collen AFS, Schuttelaar MA, de Graaf M, de Bruin-Weller MS.   +23 more
europepmc   +2 more sources

Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials [PDF]

, 2022
Introduction: This integrated analysis describes the safety profile of upadacitinib, an oral Janus kinase inhibitor, at 15 and 30 mg once daily for up to 3 years of exposure in patients with active psoriatic arthritis (PsA) who had a prior ...
Azevedo V. F., Blanco R., Burmester G. R., Goupille P., Lertratanakul A., Lesser E., Lippe R., Liu J., Mccaskill R. M., Nash P., Rubbert-Roth A., Ruderman E. M., Salvarani C., Winthrop K.   +13 more
core   +1 more source

Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib [PDF]

, 2023
Background and Objectives: JAK inhibitors entered current clinical practice as treatment for several immune-related diseases and, recently, for atopic dermatitis.
Ianiro G.
core   +4 more sources

Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study

RMD Open
Objectives To assess the safety and efficacy of upadacitinib versus adalimumab from SELECT-COMPARE over 5 years.Methods Patients with rheumatoid arthritis and inadequate response to methotrexate were randomised to receive upadacitinib 15 mg once daily ...
Roy Fleischmann, Patrick Durez, Eduardo Mysler, Louis Bessette, Yihan Li, Nasser Khan, Charles G Peterfy, Jerzy Swierkot, Xianwei Bu, Sara K Penn   +9 more
doaj   +1 more source

Upadacitinib in Patients With Difficult-to-Treat Crohn's Disease [PDF]

Upadacitinib has recently been approved for treating Crohn's disease (CD). Here, we report on the effectiveness and safety of upadacitinib in a cohort of patients with difficult-to-treat CD being cared for at clinical centers across ...
Aratari, Annalisa, Armuzzi, Alessandro, Balestrieri, Paola, Barberio, Brigida, Bertani, Lorenzo, Bezzio, Cristina, Biscaglia, Giuseppe, Bodini, Giorgia, Calabrese, Emma, Campigotto, Michele, Cappello, Maria, Caprioli, Flavio Andrea, Casini, Valentina, Cavalli, Carolina, Ceccarelli, Linda, Conforti, Francesco Simone, Danese, Silvio, Franchellucci, Gianluca, Furfaro, Federica, Marzo, Manuela, Mastronardi, Mauro, Michielan, Andrea, Principi, Maria Beatrice, Saibeni, Simone, Savarino, Edoardo V, Scaldaferri, Franco, Soriano, Alessandra, Variola, Angela   +27 more
core   +5 more sources

Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis:52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2) [PDF]

Background: Atopic dermatitis is a chronic inflammatory disease characterized by increased itch, skin pain, poor sleep quality, and other symptoms that negatively affect patient quality of life.
Bunick, CG, Calimlim, BM, Deleuran, M, Gold, LFS, Gooderham, MJ, Grada, A, Hijnen, D, Hu, Xiaofei, Lee, Wan-Ju, Paller, AS, Platt, AM, Silverberg, JI, Teixeira, HD, Thaçi, D, Yang, Y, Zhang, Shiyu   +15 more
core   +4 more sources

Janus kinase inhibitors: a new tool for the treatment of axial spondyloarthritis [PDF]

, 2023
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease involving the spine, peripheral joints, and entheses. This condition causes stiffness, pain, and significant limitation of movement.
Accapezzato D., Caccavale R., Paroli M., Paroli M. P., Spadea L.   +4 more
core   +1 more source

Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients

RMD Open
Objectives To evaluate the effectiveness and safety of upadacitinib in treatment-refractory inflammatory myositis.Methods Patients with refractory inflammatory myositis treated with upadacitinib from a single urban centre in Vancouver, British Columbia ...
Kun Huang, Jan Dutz, Madelaine Beckett
doaj   +1 more source

Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease

RMD Open
Objectives Evaluate the risks and benefits of upadacitinib 15 mg vs adalimumab in rheumatoid arthritis (RA) patients with an inadequate response to methotrexate based on cardiovascular (CV) risk.Methods In SELECT-COMPARE, patients received upadacitinib ...
Roy Fleischmann, Stephen Hall, Gerd R Burmester, Eduardo Mysler, Peter Taylor, Tianming Gao, Sander Strengholt, Bettina Wick-Urban, Andrew Garrison, Irina Fish   +9 more
doaj   +1 more source

Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial

Arthritis Research & Therapy
Background To evaluate the efficacy and safety of upadacitinib monotherapy versus methotrexate (MTX) monotherapy over 5 years among MTX-naïve patients with moderately to severely active rheumatoid arthritis (RA) in the long-term extension (LTE) of the ...
Ronald van Vollenhoven, Vibeke Strand, Tsutomu Takeuchi, Nilmo Chávez, Pablo Mannucci Walter, Atul Singhal, Jerzy Swierkot, Nasser Khan, Xianwei Bu, Yihan Li, Sara K. Penn, Heidi S. Camp, Jacob Aelion   +12 more
doaj   +1 more source